Takeda
Also known as: Laboratoires Takeda | Millennium Pharmaceuticals, Inc. | Millennium: The Takeda Oncology Company | PT. Takeda Indonesia | Takeda | TAKEDA | Takeda Bio Development Center, Ltd | Takeda Canada, Inc. | Takeda China (for the BP lowering arm of the study in China, from March 2016) | Takeda Development Center Americas | Takeda Development Center Americas, Inc. | Takeda Development Center Americas (TDCA) | Takeda Development Center Asia, Pte Ltd. | Takeda Global Research and Development | Takeda Global Research and Development Center, Inc. | Takeda Global Research and Developmnet Center Inc | Takeda Global Research & Development Center | Takeda Global Research & Development Center (Europe), Ltd. | Takeda Global Research & Development Centre (Europe) | Takeda Italia Farmaceutici SpA | Takeda Kasei | Takeda Nycomed | Takeda Pharma | Takeda Pharmaceutical Company Limited (Japan) | Takeda Pharmaceuticals Company Limited | Takeda Pharmaceuticals Company Ltd. | Takeda Pharmaceuticals International, Inc. | Takeda Pharmaceuticals Limited | Takeda Pharmaceuticals North America, Inc. | Takeda Pharmaceuticals U.S.A., Inc. | Takeda Pharma Gmbh, Aachen (Germany) | Takeda Pharma GmbH, Aachen (Germany) | Takeda Pharma GmbH (Germany) | TAKEDA PHARMS NA | TAKEDA PHARMS USA | Todd Doyle
Highest phase reached
Phase 4
First clinical trial
Dec 1, 1996First marketed drug
Mar 3, 1954First NDA
Dec 21, 1979Last known activity
May 1, 2026
Timeline
1780s
- Jan 1, 1781
Takeda— Founded
1970s
- Dec 21, 1979
anti-inhibitor coagulant complex (activated prothrombin complex concentrate)— NDA Organization
2000s
- Feb 7, 2005
Syrrx— Acquired
- Jan 1, 2008
TAP Pharmaceuticals— Acquired
- May 9, 2008
Millennium Pharmaceuticals— Acquired - May 18, 2009
IDM Pharma— Acquired
2010s
- Oct 3, 2011
Nycomed (1999)— Acquired
- Dec 21, 2011
Intellikine— Acquired
- Apr 11, 2012
URL Pharma— Acquired
- May 25, 2012
Multilab— Acquired
- Oct 8, 2012
LigoCyte— Acquired - Nov 7, 2012
Envoy Therapeutics— Acquired
- May 8, 2013
Inviragen— Acquired
- Feb 1, 2017
Ariad Pharmaceuticals— Acquired
- Apr 28, 2017
brigatinib— Marketing Organization
- Apr 28, 2017
brigatinib— NDA Secondary Org
- Jan 5, 2018
TiGenix— Acquired
- Dec 3, 2018
Shire— Acquired
2020s
- Feb 25, 2020
PvP Biologics, Inc.— Acquired
- Mar 9, 2021
Maverick Therapeutics— Acquired
- Nov 1, 2021
GammaDelta Therapeutics— Acquired
Drugs by trial phase (647 distinct, 2207 trials)
Phase 4 (44 own, 100 via acquisition)
Phase 3 (68 own, 114 via acquisition)
Phase 2 (67 own, 119 via acquisition)
Phase 1 (53 own, 75 via acquisition)
Other trials (4 own, 3 via acquisition)
Indications
Approved for
- Adrenoleukodystrophy
- Colitis, Ulcerative
- Crohn Disease
- Cystitis
- Diabetes Mellitus, Type 2
- Duodenal Ulcer
- Esophagitis
- Gastroesophageal Reflux
- Heartburn
- Hypertension
- Hyperuricemia
- Major Depressive Disorder
- Multiple Myeloma
- Respiratory Tract Infections
- Sleep Disorders, Intrinsic
- Sleep Initiation and Maintenance Disorders
- Stomach Ulcer
Studied for
- Acute Coronary Syndrome
- Adenocarcinoma
- Adenocarcinoma, Clear Cell
- Alzheimer Disease
- Amyloidosis
- Anemia
- Anemia, Hemolytic
- Anemia, Hemolytic, Autoimmune
- Angina Pectoris
- Angina, Stable
- Angioedema
- Angioedemas, Hereditary
- Anhedonia
- Anxiety Disorders
- Apnea
- Arterial Occlusive Diseases
- Arthritis
- Arthritis, Rheumatoid
- Asthma
- Ataxia
- Atherosclerosis
- Atrial Fibrillation
- Attention Deficit Disorder with Hyperactivity
- Autoimmune Diseases
- Back Pain
- Barrett Esophagus
- Binge-Eating Disorder
- Bipolar Disorder
- Blast Crisis
- Body Weight
- Brain Diseases
- Brain Injuries
- Brain Injuries, Traumatic
- Breakthrough Pain
- Breast Neoplasms
- Bulimia
- Burkitt Lymphoma
- Calculi
- Caliciviridae Infections
- Carcinoma
- Carcinoma, Acinar Cell
- Carcinoma, Endometrioid
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Carcinoma, Transitional Cell
- Carcinosarcoma
- Cardiovascular Diseases
- Celiac Disease
- Cerebellar Ataxia
- Cholangitis
- Cholangitis, Sclerosing
- Chronobiology Disorders
- Cognitive Dysfunction
- Colitis
- Colitis, Ulcerative
- Colorectal Neoplasms
- Communicable Diseases
- Complex Regional Pain Syndromes
- Constipation
- Coronary Artery Disease
- Coronary Disease
- Coronavirus Infections
- Craniocerebral Trauma
- Crohn Disease
- Cystadenocarcinoma, Serous
- Deficiency Diseases
- Dengue
- Depression
- Depressive Disorder
- Depressive Disorder, Treatment-Resistant
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
- Diabetic Nephropathies
- Diabetic Neuropathies
- Diabetic Retinopathy
- Digestive System Diseases
- Disease
- Disease Progression
- Disorders of Excessive Somnolence
- Duodenal Ulcer
- Dyslipidemias
- Dyspepsia
- Dyssomnias
- Endocrine Gland Neoplasms
- Endometriosis
- Enteritis
- Ependymoma
- Epilepsies, Myoclonic
- Epilepsy
- Erectile Dysfunction
- Esophageal Neoplasms
- Esophagitis
- Esophagitis, Peptic
- Essential Hypertension
- Fallopian Tube Neoplasms
- Fatty Liver
Marketed drugs (69)
- metformin
- sumatriptan
- anagrelide
- antihemophilic factor viii (Recombinant), porcine sequence
- azilsartan
- bendamustine
- coagulation factor ix (Recombinant)
- procaine benzylpenicillin
- brigatinib
- cefotiam
- norepinephrine
- C1 Esterase Inhibitor (Human)
- dexlansoprazole
- alpha-1 antitrypsin
- ecallantide
- fruquintinib
- parathyroid hormone
- glimepiride
- mesalamine
- guanfacine
Subsidiaries (17 direct, 72 total across the full acquisition tree)
- Ariad Pharmaceuticals
- Envoy Therapeutics
- GammaDelta Therapeutics
- IDM Pharma
- Intellikine
- Inviragen
- LigoCyte
- Maverick Therapeutics
- Millennium Pharmaceuticals
- Multilab
- Nycomed (1999)
- PvP Biologics, Inc.
- Shire
- Syrrx
- TAP Pharmaceuticals
- TiGenix
- URL Pharma
- Advanced BioHealing L2
- Altana L2
- Baxalta L2
- Bradley Pharmaceuticals L2
- Cambridge Discovery Chemistry L2
- Cellerix L2
- COR Therapeutics L2
- Dyax L2
- Epimmune L2
- FerroKin BioSciences L2
- Fibrotech L2
- Foresight Biotherapeutics L2
- Jerini L2
- Leukosite L2
- Lotus Tissue Repair, Inc L2
- Lumena Pharmaceuticals L2
- Magnetic Imaging Technologies, Inc (MITI) L2
- Meritage Pharma L2
- Movetis L2
- New River Pharmaceuticals L2
- NPS L2
- NPS Pharma L2
- Orthomimetics L2
- Pervasis Therapeutics, Inc L2
- Pharmavene L2
- Premacure AB L2
- Richwood Pharmaceutical Company L2
- Roberts Pharmaceutical L2
- Sanaplasma AG L2
- SARcode Bioscience L2
- ViroPharma L2
- AesRx L3
- Allelix L3
- American Hospital Supply L3
- Anaquest L3
- Apatech L3
- Archemix Corp. L3
- Ascot Pharmaceuticals L3
- Byk L3
- Chatham Therapeutics L3
- Doak Pharmacal L3
- DuoCort Pharma L3
- Enzon L3
- Flowsense L3
- Gambro L3
- Immuno AG L3
- Immuno US, Inc. L3
- Lev Pharmaceuticals L3
- Osterreichisches Institut fur Haemoderivate L3
- Pardes Biosciences, Inc. L3
- Pinnacle Pharmaceuticals L3
- Prism Research L3
- SuppreMol L3
- Target Quest, BV L3
- Arnar Stone L4
Recent trials (50)
- NCT06955793OfficialN/A—
- NCT06955793Lead sponsorN/A—
- NCT06173024Lead sponsorN/A—
- NCT06173024Study directorN/A—
- NCT06856135Lead sponsorN/A—
- NCT06856135OfficialN/A—
- NCT05795361Lead sponsorN/A—
- NCT05795361Study directorN/A—
- NCT05770219Lead sponsorN/A—
- NCT05770219Study directorN/A—
- NCT06195514Lead sponsorN/A—
- NCT06195514OfficialN/A—
- NCT04583007CollaboratorN/A—
- NCT04484363Study directorN/A—
- NCT07224100CollaboratorPhase 2May 1, 2026
Details
- Founded
- Osaka, JP Jan 1, 1781
- First NDA
- Dec 21, 1979
- Last known activity
- May 1, 2026
Designations held
- Orphan drug
- Fast track
- Priority review
- Breakthrough therapy
- Accelerated approval